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Available online 15 January 2016Improvement in transduction efﬁciency makes it possible to convert blood cells into induced pluripotent stem
cells (iPSC). In this study, we generated an iPSC line from peripheral blood mononuclear cells (PBMC) donated
by a patient who exhibited memory deﬁcit at age 59; outcome of positron emission tomography scan is consis-
tent with a diagnosis of Alzheimer's disease. Integration-free CytoTune-iPS Sendai Reprogramming factorswhich
include Sendai virus particles of the four Yamanaka factors Oct4, Sox2, Klf4, and c-Mycwere introduced to PBMC
to convert them to iPSCswithout retention of virus. Three germ layer differentiationwas induced to demonstrate
the pluripotency of these iPSCs.
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The blood sample was donated by the patient who was hospitalized
at the Bedford VA Hospital Special Dementia Care Unit, which is an Clinical Center, Edith Nourse
00 Springs Road, Bedford, MA
ss article under the CC BY-NC-ND lichospice unit staffed and managed by the Bedford Geriatric Research,
Education and Clinical Center (GRECC).
The patient exhibited memory deﬁcit at age 59 that prevented him
from performing job-related function. Subsequent neurological tests
and positron emission tomography (PET) scan presented clinical diag-
nosis consistent with Alzheimer's disease. The patient also suffered
two witnessed seizures which were controlled by anti-epileptic drug
levetiracetam. The study was approved by the Bedford Veterans Affairs
Hospital Institutional Review Board under the project title, “iPSC for
Neurodegenerative diseases”.
Peripheral blood mononuclear cells (PBMC) were separated from
whole blood and transduced by reprogramming vectors carrying four
Yamanaka factors, Oct4, Sox2, Klf4, and c-Myc included in the
CytoTune-iPS 2.0 Sendai Reprogramming Kit (Invitrogen). The four
Yamanaka factors have been well documented for efﬁcient
reprogramming of skin ﬁbroblasts and blood cells (Trokovic et al.,
2014; Lieu et al., 2013; Takahashi et al., 2007).
We conﬁrmed development of human iPSC by karyotyping (Fig. 1),
which is a standard procedure to authenticate normal karyotypes of
cells (Li et al., 2011). To validate bona ﬁde iPSCs in our culture that is
distinguishable from only partially transduced cells, we examined the
expression of cell surface proteins, such as sialylated keratan sulfate
antigens Tra-1-81 and Tra-1-60, which deﬁnes a human embryonic
stem cell (Badcock et al., 1999; Nethercott et al., 2011; Sommer et al.,
2012). Immunocytochemical staining using antibody against stem cell
marker TRA-1-81 (Fig. 2A) and Tra-1-60 (not shown) was performed
to conﬁrm the purity and pluripotency of our iPSC.
Many approaches have been developed to produce footprint-free
iPSC (Ovchinnikov et al., 2015), and we applied the CytoTune-iPS 2.0
Reprogramming System for our studies (Seki et al., 2010). This systemense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Karyotyping of Inducedpluripotent stemcell I2-12F. Cellswere stainedwithGiemsa
and the metaphase chromosome number from individual nuclei were imaged and
counted. All ten metaphase cells had 46 chromosomes and XY sex chromosomes
characteristic of a male patient.
Fig. 3. Characterization of embryoid body (EB) formation. EBs was ﬁxed with 4% PFA and
immunostained with three different antibodies (ectoderm: β III tubulin, green;
mesoderm: smooth muscle actin (SMA), red; endoderm: α-fetoprotein (AFP) green).
Con: cells were stained in the absence of primary antibodies.
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integrate into host genome (Fusaki et al., 2009). Therefore, the host
cell can be cleared of the vectors and reprogramming factor genes (Li
et al., 2000). We searched for any remaining SeV protein by immunocy-
tochemical staining using Anti-SeV antibody (MBL international) and
conﬁrmed that there is no trace of viral protein (Fig. 2B).
To demonstrate capacity of iPSC for three germ layer differentiation,
we tested formation of embryoid body (EB) (Hribar et al., 2015).We per-
formed immunostaining using three different antibodies corresponding
to three germ layers, i.e., ectoderm: βIII tubulin antibody, mesoderm:
smooth muscle actin (SMA) antibody, endoderm: α-fetoprotein (AFP)
antibody. Our results demonstrated differentiation capacity of newly
converted iPSC (Fig. 3).Fig. 2. Characterization of iPSC I2-12F. Stem cell surface protein Sialylated Keratan Sulfate Antig
Sendai virus protein, detected by antibody against SeV protein (B, left), compared to positive c3. Materials and methods
3.1. Human blood sample
Blood was collected in Vacutainer cell preparation tube (CPT)
(Becton, Dickinson and Company, Franklin Lakes, NJ). PBMCs were pre-
pared within 1 h of blood collection. Blood samples were centrifuged at
1500 rcf for 20 min at room temperature, and the PBMC were collecteden Tra-1-81 was present in all iPSC I2-12F (A, left; bright ﬁeld: right). There is no trace of
ells of early stage (at passage ﬁve) when SeV protein was present.
215H.-K. Lee et al. / Stem Cell Research 16 (2016) 213–215and transferred to a fresh tube, washed with PBS, and centrifuged at
300 rcf for 10 min at room temperature. Cell pellets were re-suspended
in PBMCmedium(Invitrogen) containing growth factors for transduction.
3.2. iPSC generation and expansion
Induced PSCs were generated from freshly collected, peripheral
blood-derived PBMCs (Chou et al., 2011). Cells were transduced with
Sendai virus particles containing four Yamanaka factors using the
integration-free CytoTune-iPS Sendai Reprogramming Kit (Lieu et al.,
2013; Takahashi et al., 2007). Transduced cells were plated with
mouse embryonic ﬁbroblast (MEF) feeder cells. Cells were fed with
iPSC medium containing bFGF (Invitrogen) until small colonies were
formed in 2 weeks. Growth of small colonies wasmaintained for another
two weeks before each colony was picked for expansion into individual
iPSC lines. After successful formation of iPSC colonies, iPSCs were trans-
ferred to plates coatedwith Geltrex (Invitrogen) and expanded in E8me-
dium (Invitrogen).
3.3. Live staining of iPSC
Purity and pluripotency of iPSCs grown on bothMEF feeder cells and
Geltrex coated plateswere conﬁrmedby live stainingwith Tra-1-81 and
Tra-1-60 antibodies (Invitrogen). Cells were washed with Knockout
DMEM and stained with Tra-1-81 or Tra-1-60 antibodies at 1:200
dilutions for 1 h in the CO2 incubator. Cells were subsequently washed
twice with Knockout DMEM and incubated with secondary anti-
mouse antibody conjugated with Alexa Fluor 488 for one hour. Finally,
cells were washed with Knockout DMEM and replenished with iPSC
growth medium for microscopic imaging. Images were acquired using
a Leica TCS SP5 Confocal Laser Scanning Microscope.
3.4. iPSC karyotyping
Karyotyping of the iPSC was carried out at the CytoGenomics Core
Laboratory (Brigham and Women's Hospital, Harvard Medical School,
Boston, MA). G-banding was used to karyotype our iPSC line. Cells in a
stage of active division in metaphase were arrested, harvested and
ﬁxed with methanol:acetic acid (3:1). The cell pellet was washed, re-
suspended, dropped on a slide and dried on a hotplate. Cells were
stained with Giemsa and the metaphase chromosome number from
individual nuclei were imaged (Olympus BX51, 100×) and counted
using the Cyto Vision Software.
3.5. Three germ layer in vitro differentiation and characterization
The differentiation capability of iPSC lines was analyzed by the
formation of EB, based on the previously published protocol (Carpenter
et al., 2003; Itskovitz-Eldor et al., 2000). Brieﬂy, undifferentiated iPSC
colonies were transferred into the non-adherent poly-HEMA (Sigma)
coated petri dish and were cultured in E6 medium without bFGF for
7 days. The resulting EB, which theoretically comprise three embryonic
germ layers, were plated onto Geltrex coated tissue culture dishes and
cultured for spontaneous differentiation. After cells were differentiated
in EB culture for a total of 19 days, cells were ﬁxed with 4% PFA and
immuostained with three different antibodies (Ectoderm: β III tubulin,
Sigma; Mesoderm: Smooth muscle actin, Invitrogen; Endoderm: Alpha
fetoprotein, Invitrogen). Images were acquired using the Nikon TMS,10×; the Leica TCS SP5 Confocal Microscope, 10×; and the AmScope
microscope digital camera.
4. Veriﬁcation and authentication
Karyotyping of our iPSC was performed and revealed by the micro-
scope scan. All ten metaphase cells had 46 chromosomes and had XY
sex chromosomes characteristic of a male patient (Fig. 1).
We examined embryonic stem cell makers, Tra-1-81 and Tra-1-60
by live staining of cells and found all cells are Tra-1-81 (Fig. 2A) and
Tra-1-60 (not shown) positive, thus conﬁrming iPSC purity and
pluripotency.
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